Back to top
more

BioCryst Pharmaceuticals (BCRX)

(Delayed Data from NSDQ)

$7.52 USD

7.52
2,703,663

-0.33 (-4.20%)

Updated Jul 29, 2024 04:00 PM ET

After-Market: $7.51 -0.01 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BCRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

BioCryst Pharmaceuticals, Inc. [BCRX]

Reports for Purchase

Showing records 41 - 60 ( 176 total )

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 41

02/28/2018

Company Report

Pages: 5

Thinking Through Discovery Effort Synergies; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 42

01/23/2018

Daily Note

Pages: 4

NewCo Combines HAE Commercial - Deal-Making Expertise With Core Competency in Structure-Based Drug Design

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 43

11/08/2017

Company Report

Pages: 5

Oral Prophylactic Has HAE Patients Coming out of the Dark; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 44

11/06/2017

Industry Report

Pages: 4

Peanut Allergy and HAE Updates from ACAAI Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 45

09/06/2017

Daily Note

Pages: 3

ApeX-1 Brings Data Consistency and Dose Clarity for Phase 3; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 46

08/08/2017

Company Report

Pages: 6

Our Blueprint for Apex-1 Part Three: Consistency

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 47

05/26/2017

Daily Note

Pages: 4

Apex-1 Part Deux Gives Clearer and Cleaner Snapshot of 7353; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 48

05/19/2017

Company Report

Pages: 4

Shire Data Remove Important Overhang Ahead of Next Apex-1 Update in 2Q; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 49

02/28/2017

Company Report

Pages: 6

We Remain Bullish Ahead of Next Apex-1 Update in 2Q

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 50

11/08/2016

Company Report

Pages: 6

Apex-1 POC Data In 1Q17, HAE Value Proposition Unchanged

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 51

08/05/2016

Company Report

Pages: 6

A Simpler and Cleaner HAE Story Going Forward

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 52

05/06/2016

Company Report

Pages: 5

1Q16 Update: Thinking of Value Beyond HAE

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 53

02/24/2016

Company Report

Pages: 7

Moving Forward with Lessons Learned; Reiterate Buy Rating and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 54

02/09/2016

Company Report

Pages: 6

Trying to See the Forest For the Trees; We Maintain Buy Rating and Lower PT to $10

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 55

11/24/2015

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 56

11/09/2015

Company Report

Pages: 5

Reframing Our Bull Thesis in Light of the Current Valuation Disconnect

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 57

10/09/2015

Daily Note

Pages: 4

The Once-Daily Oral Kallikrein Inhibitor Is Here

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 58

08/10/2015

Company Report

Pages: 5

A Thorough Phase 1 Is a Good Phase 1; Reit Buy and $24 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 59

05/11/2015

Company Report

Pages: 7

1Q15 Update: Medium-Term And Long-Term Approaches to Value With Oral HAE Prophylaxis

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 60

04/01/2015

Daily Note

Pages: 4

Our Thoughts on Yesterday?s Dyax Phase 1b Readout

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party
// eof